Zielbio, Inc., A Clinical Stage Biotechnology Company, Announced The First Patient Dosed In Its Phase 1/2 Clinical Trial. The Study Will Evaluate Zb131 In Patients With Solid Tumours Who Are Either Non-Responsive To Or Ineligible For The Standard Of Care.Zb131 Is A Monoclonal Antibody With A High Affinity And Specificity For Cancer Specific Plectin (Csp), A Cell Surface Protein Identified In A Wide Range Of Cancers That Correlates With Poor Prognosis And Aggressive Tumours.
